Latest filing published 28 Oct 2019 for Bellerophon Therapeutics, Inc., €318k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Venrock Associates IV L P: trading record in brief
Filings by Venrock Associates IV L P span 5 companies, the busiest being Bellerophon Therapeutics, Inc., Anacor Pharmaceuticals, Inc. and Quantenna Communications Inc. We count 60 filings; the first trade dates from 27 April 2010 and the latest from 28 October 2019.
In open-market terms, that means 28 purchases worth €7.3M on one side and 11 sales worth €2.9M on the other. Purchases outweigh sales by €4.3M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. 2019 to date brings 2 purchases and 6 sales.
Half of the purchases are above €78k and half below. Of 13 purchases, 1 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The latest filing, published on 28 October 2019, reports an open-market sale of €318k in Bellerophon Therapeutics, Inc. The most recent open-market purchase was published on 14 March 2019, 2,796 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Venrock Associates IV L P
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 704,595 shares@ US$0.501511.0% of flowCommon StockSEC:0001209191-19-054264:0
- 56,242 shares@ US$0.45360.8% of flowCommon StockSEC:0001209191-19-054264:1
- 333,010 shares@ US$0.43874.6% of flowCommon StockSEC:0001209191-19-054264:2
- 142,857 shares@ US$0.705.2% of flowCommon StockSEC:0001209191-19-019528:0Canonical exit: 23 Apr 2019 (T+90)
- 75,000 shares@ US$1.18884.5% of flowCommon StockSEC:0001209191-18-051215:0Canonical exit: 12 Dec 2018 (T+90)
- 75,000 shares@ US$1.234.7% of flowCommon StockSEC:0001209191-18-051215:1Canonical exit: 13 Dec 2018 (T+90)
- 60,000 shares@ US$1.18243.6% of flowCommon StockSEC:0001209191-18-051215:2Canonical exit: 16 Dec 2018 (T+90)
- 200,000 shares@ US$1.218212.5% of flowCommon StockSEC:0001209191-18-050737:0Canonical exit: 9 Dec 2018 (T+90)
- 200,000 shares@ US$1.144211.8% of flowCommon StockSEC:0001209191-18-050737:1Canonical exit: 10 Dec 2018 (T+90)
- 75,000 shares@ US$1.14554.4% of flowCommon StockSEC:0001209191-18-050737:2Canonical exit: 11 Dec 2018 (T+90)
- 50,000 shares@ US$0.84652.2% of flowCommon StockSEC:0001209191-18-050120:0Canonical exit: 4 Dec 2018 (T+90)
- 50,000 shares@ US$0.84192.2% of flowCommon StockSEC:0001209191-18-050120:1Canonical exit: 5 Dec 2018 (T+90)
- 60,000 shares@ US$0.89572.8% of flowCommon StockSEC:0001209191-18-050120:2Canonical exit: 6 Dec 2018 (T+90)
- 190,977 shares@ US$0.64866.5% of flowCommon StockSEC:0001209191-18-047215:0Canonical exit: 12 Nov 2018 (T+90)
- 272,000 shares@ US$0.64679.2% of flowCommon StockSEC:0001209191-18-047215:1Canonical exit: 13 Nov 2018 (T+90)
- 66,393 shares@ US$0.64932.3% of flowCommon StockSEC:0001209191-18-047215:2Canonical exit: 14 Nov 2018 (T+90)
- 608,340 sharesCommon StockSEC:0001209191-16-148511:0
- 138,696 sharesCommon StockSEC:0001209191-16-148511:1
- 186,644 sharesCommon StockSEC:0001209191-16-148511:2
- 805,625 sharesCommon StockSEC:0001209191-16-148511:3
- 469,779 sharesCommon StockSEC:0001209191-16-148511:4
- 383,634 sharesCommon StockSEC:0001209191-16-148511:5
- 60,551 sharesCommon StockSEC:0001209191-16-148511:6
- 725,873 sharesCommon StockSEC:0001277997-14-000002:2
- 340,797 sharesCommon StockSEC:0001277997-14-000002:0
25 of 40 declarations
